サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1133475

レッドバイオテクノロジーの世界市場-2022-2029

Global Red Biotechnology Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 250 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
レッドバイオテクノロジーの世界市場-2022-2029
出版日: 2022年10月11日
発行: DataM Intelligence
ページ情報: 英文 250 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

レッドバイオテクノロジー市場の成長は、慢性疾患の有病率の上昇、老人人口の増加、標的療法の研究開発活動、医療制度の急速な拡大、生物製剤の技術的進歩によってもたらされています。

慢性疾患や希少疾患に対する助成金の増加が市場成長の原動力になると予想される

がんや心血管疾患など、さまざまな疾患の有病率の上昇は、予測期間中に市場を押し上げると予想されます。2021年の希少疾患データ報告書によると、世界保健機関（WHO）は、希少疾患とは、人口1000人あたり1人以下の頻度の生涯疾患または障害であると報告しています。米国では、希少疾患は、国内の患者数が20万人未満（人口1万人に6.4人）の疾患または状態とされています。EUでは、生命を脅かす、または慢性的に疲弊している状態で、1万人に5人以下が罹患する疾患を希少疾患と定めています。日本では、国内の有病者数が5万人未満（0.04％）の疾患を希少疾患と定義しています。

また、2021年にはNICE（National Institute for Health and Care Excellence）が最終ガイダンスを発表するなど、各当局が希少疾患への資金提供に向けた取り組みを行っています。シンガポールでは、3つの希少疾患の治療薬5品目を対象とした希少疾患ファンドが創設され、マレーシアやオーストラリアでは、高コストで救命効果の高い医薬品について、適格患者への補助金アクセスが提供されています。さらに、慢性疾患の場合、CDCによると、全米の年間3兆8,000億米ドルの医療費の90%は、慢性疾患や精神疾患を持つ人々に割り当てることができるとされています。最近の慢性疾患対策出版物の共同研究では、7つの主要な一般的慢性疾患の治療は、生産性の損失と相まって、2030年までに年間2兆ドル、1人当たり8,600米ドルの米国経済への負担となると決定しています。希少疾患や慢性疾患に対する助成金の増加は、世界のレッドバイオ市場を後押しすることになります。

希少疾病の認知者不足が市場成長の妨げとなる

しかし、希少疾患の場合、プライマリーケアの医療従事者の認識不足、スクリーニングや診断のための施設不足など、多くの要因から早期診断が主な課題となっています。また、患者数が限られているため新薬の開発が難しく、長期的な安定性が求められる慢性的な希少疾患であればあるほど、その課題は大きくなっています。これがレッドバイオテクノロジー市場を制限する要因となっています。

COVID-19の影響分析

COVID-19の出現は、世界のレッドバイオテクノロジー市場に大きな影響を与えました。COVID-19のパンデミックの間、バイオテクノロジー企業が感染症研究に追随するための大規模な軸足があっています。COVID-19ワクチン候補の多くと、さまざまな治療法やワクチンに関する800以上の臨床試験は、感染症分野での経験がない企業によって開発されていました。明らかに、これらの製品や企業のうち、開発、資金調達、規制上の成功を収めるものは多くはないと思われます。また、McMurry-Heath（BIO CEO）は、COVID-19疾患が複雑であるため、複数の種類の薬剤メカニズムが効果を発揮する役割が認められていると言及しました。新たな治療薬やワクチン候補という形で、この新たな焦点の成果が見え始めました。一方、COVID-19のパンデミックは、世界中のバイオテクノロジストたちにユニークな機会を提供しています。世界は、人類がこの危機と戦い、コントロールするのに役立つ効果的なソリューションを開発するために、バイオテクノロジー部門に期待しているのです。さらに、研究機関、政府機関、製薬会社を含むバイオテクノロジー産業が協力して、検出ツール、医薬品、ワクチンを開発し、この紛争に立ち向かっているのです。このように、バイオテクノロジーはCOVID-19との闘いにおいて、優れた存在として注目されています。Zydus Cadila、Serum Institute、Biological E、Bharat Biotech、Indian Immunologicals、Mynvaxなどインドの6社はCOVID-19のワクチン開発に取り組んでおり、世界中で急速に広がっているこの致命的な感染症の迅速な予防法の開発に向けた世界の取り組みに貢献しています。

世界のレッドバイオテクノロジー市場レポートは、約60以上の市場データ表、55以上の図、250ページ（概算）の範囲でのアクセスを提供することになります。

目次

第1章 市場調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • 製品タイプ別市場内訳
  • アプリケーション別市場内訳
  • エンドユーザー別市場内訳
  • 地域別市場内訳

第4章 市場力学

  • 市場インパクトファクター
    • 促進要因
      • 慢性疾患の発生率の上昇
      • 研究活動の増加
    • 抑制要因
    • 技術や機械のコスト高
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 規制分析
  • プライシング分析
  • アンメットニーズ分析

第6章 COVID-19分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、あるいは将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 製品タイプ別

  • 血液製剤
  • 遺伝子組換え医薬品
  • ヒトワクチン
  • 診断用試薬
  • パーソナライズドメディシン
  • その他

第8章 アプリケーション別

  • ファーマコゲノミクス
  • バイオ医薬品製造
  • 遺伝子検査
  • 遺伝子治療

第9章 エンドユーザー別

  • 研究機関
  • CMO・CRO
  • バイオ製薬企業
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • 欧州の他の地域
  • 南米
    • 地域別主要指標
      • ブラジル
      • アルゼンチン
      • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 治療タイプ別ベンチマーク

第12章 企業プロファイル

  • Hoffmann-La Roche, Ltd.
    • 企業概要
    • 治療タイプのポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Merck KGaA
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Biogen Inc.
  • Amgen Inc.
  • AstraZeneca Plc.
  • Takeda Pharmaceutical Company Ltd.
  • Gilead Sciences, Inc.
  • Celgene Corporation

第13章 世界のレッドバイオテクノロジー市場-DataM

目次
Product Code: DMMD5856

Market Overview

Red Biotechnology Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.2% during the forecast period (2022-2029).

Red biotechnology indicates biopharmaceuticals. It involves the use of biotechnology in the medical field. It covers applications of biotechnology relating to clinical trials, vaccine development, disease research, antibiotic production, drug development, and molecular diagnostics.

Market Dynamics

The red biotechnology market growth is driven by the rise in prevalence of chronic disease, increase in the geriatric population, research and development activities for targeted therapies, rapid expansion in the healthcare system and technological advancements in biologics.

The rising funding for chronic and rare diseases is expected to drive the market growth

The rising prevalence of different diseases such as cancer and cardiovascular diseases is expected to boost the market over the forecast period. As per the 2021 rare disease data report, the World Health Organization (WHO) reports that a rare disease is a lifelong disease or disorder with a frequency of 1 or less per 1000 populations. In the United States, rare diseases are considered diseases or conditions that affect fewer than 200,000 patients in the country (6.4 in 10,000 people). The EU identifies rare diseases as life-threatening or chronically exhausting conditions affecting no more than 5 in 10,000 people. Japan defines rare diseases as diseases with fewer than 50,000 prevalent cases (0.04%) in the country.

In addition, the various authorities take initiatives for funding for rare diseases, such as in 2021, the National Institute for Health and Care Excellence (NICE) publication of final guidance. In Singapore, a rare disease fund was created to fund five medicines to treat three rare disease conditions, and in Malaysia and Australia, subsidised access for eligible patients is offered for high-cost and lifesaving drugs. Moreover, in the case of chronic diseases, according to the CDC, 90% of the nation's $3.8 trillion per year healthcare costs can be allotted to people with chronic diseases and mental health conditions. A recent collaboration to fight chronic disease publication decided that treatment of the seven major common chronic diseases, coupled with productivity losses, will cost the U.S. economy 2 trillion dollars annually, or USD 8,600 per person by 2030. Increasing the funding for rare and chronic diseases will boost the red biotechnology market worldwide.

The lack of awarenees of rare diseases will hamper the growth of the market

However, in the case of rare diseases, early diagnosis is the main challenge due to many factors, such as lack of awareness in primary care health care professional and lack of facilities for screening and diagnosis. In addition, it is difficult to develop a new drug due to a limited patient pool and the challenge becomes more greater when rare diseases are chronic in nature, where long-term stability is required. This factor limiting the red biotechnology market groeth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global red biotechnology market. During the COVID-19 pandemic, there was a massive pivot by biotechnology companies to follow infectious disease research. Many of the COVID-19 vaccine candidates and over 800 clinical trials for various treatments and vaccines were under development by companies without prior experience in the infectious disease area. Clearly, not many of these products and companies will receive development, funding, or regulatory success. In addition, McMurry-Heath (CEO of BIO) mentioned that the complexity of COVID-19 disease has allowed a role for multiple types of drug mechanisms to be effective. They have only started to see the results of this new focus in terms of new therapeutics and vaccine candidates. On the other hand, the COVID-19 pandemic provides a unique opportunity to biotechnologists across the globe. The world is looking toward the biotech sector to develop effective solutions that will help human beings fight and control the crisis. Furthermore, research organizations, government agencies, and biotech industries, including pharmaceutical companies, have collaborated to fight this conflict by developing detection tools, medicines, and vaccines. Biotechnology has thus turned up as a superior in the fight against COVID-19. Six Indian companies, including Zydus Cadila, Serum Institute, Biological E, Bharat Biotech, Indian Immunologicals, and Mynvax, were working on a vaccine for COVID-19, contributing to global efforts to develop a quick preventive for the deadly infection spreading rapidly across the world.

Segment Analysis

The biopharmaceutical industries segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The biopharmaceutical industry segment is expected to boost the market over the period of the forecast. This is owing to the increased approval of different therapies for diseases such as cancer. Biopharmaceuticals are pharmaceuticals drugs that are developed by using biotechnology. Biopharmaceuticals include DNA, RNA, proteins, antibodies, or antisense oligonucleotides used for therapeutic or diagnostic purposes. A growing number of new therapies for cancer and other diseases are being introduced as a result of advanced technology and the development of novel drugs. For instance, in 2020, Tecartus was approved for mantel cell lymphoma and acute lymphocytic leukemia in the US, UK, and EU by Gilead, and in 2021, Abecma was approved for multiple myeloma in the US, Canada, EU, UK, and Japan by Bluebird Bio. Due to the approval of new therapies for cancer, it is easily available for treatment in the region, which boosts the market. Furthermore, the rising incidence and prevalence of chronic and other diseases and the rapid advancement of the biopharmaceutical industry are the key driving factors in the biopharmaceutical industry segment.

Geographical Analysis

North America region holds the largest market share of the global Red Biotechnology market

North America dominates the market for red biotechnology and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to advanced healthcare infrastructure, healthcare spending, awareness among patients, and the availability of proper treatment for rare and chronic diseases. The approval of different gene therapies drives the market in the North American region. For instance, in 2020, a retroviral vector ex vivo was approved by the FDA for mantle cell lymphoma, and in 2021, the same vector was approved for certain types of large B-cell lymphoma. In addition, to date, the FDA has received more than 900 applications for scrutinscrutinine therapy in clinical trials. Furthermore, as per the American Society of Gene & Cell Therapy (ASGCT) 2021 report, one novel genetically modified cell therapy has been approved in 2022. Carvykti, a CAR-T cell therapy developed by Legend Biotech and Johnson & Johnson, was approved for multiple myeloma in the U.S. and EtranaDez (etranacogene dezaparvovec), an AAV5 gene therapy developed by uniQure, filed for approval in the EU and UK for hemophilia B. The launch of the new product in the United States boosts the red biotechnology market in the North American region.

Competitive Landscape

The red biotechnology market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Hoffmann-La Roche, Ltd., Merck KGaA, Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Biogen Inc., Amgen Inc., AstraZeneca Plc., Takeda Pharmaceutical Company Ltd., Gilead Sciences, Inc., and Celgene Corporation among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the red biotechnology market globally.

For instance,

  • In August 2022, the U.S. FDA approved MYFEMBREE, developed by Myovant Sciences and Pfizer for the treatment of the management of moderate to severe pain associated with endometriosis. MYFEMBREE offers an efficient once-daily therapy option for the control of moderate to severe endometriosis-related pain.
  • In June 2022, Amgen's RIABNI (RITUXIMAB-ARRX), a biosimilar to RITUXAN (RITUXIMAB), received FDA approval for adults with moderate to severe rheumatoid arthritis.

Biogen Inc.

Overview:

Biogen finds, develops, and distributes worldwide innovative therapies for people living with neurological and neurodegenerative diseases as well as related therapeutic areas. The company was founded in 1978 and has the leading portfolio of medicines to treat multiple sclerosis (MS), Alzheimer's disease and dementia, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain, and ophthalmology. It also commercializes biosimilars of advanced biologics.

Treatment type Portfolio:

BENEPALI: It was approved by the European Commission (EC) in January 2016 for the treatment of adults with moderate to severe rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and plaque psoriasis. It is currently available in more than 20 countries in the Europe region and is the most recommended etanercept in the five largest European countries (Germany, UK, France, Italy, and Spain).

The global red biotechnology market report would provide access to approximately 60+ market data tables, 55+ figures, and in the range of 250 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Product Type
  • 3.2. Market snippet By Application
  • 3.3. Market snippet By End User
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising incidences of chronic diseases
      • 4.1.1.2. The increasing number of research activities
    • 4.1.2. Restraints:
    • 4.1.3. High cost of technology and machinery
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Blood Products*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Gene Recombinant Drugs
  • 7.4. Human Vaccines
  • 7.5. Diagnostics Reagents
  • 7.6. Personalized Medicines
  • 7.7. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Pharmacogenomics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Biopharmaceutical Production
  • 8.4. Genetic Testing
  • 8.5. Gene Therapy

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Research Institutes*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. CMOs & CROs
  • 9.4. Biopharmaceutical Industries
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. DRest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific ynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Treatment type Benchmarking

12. Company Profiles

  • 12.1. Hoffmann-La Roche, Ltd.*
    • 12.1.1. Company Overview
    • 12.1.2. Treatment type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Merck KGaA
  • 12.3. Regeneron Pharmaceuticals, Inc.
  • 12.4. Pfizer, Inc.
  • 12.5. Biogen Inc.
  • 12.6. Amgen Inc.
  • 12.7. AstraZeneca Plc.
  • 12.8. Takeda Pharmaceutical Company Ltd.
  • 12.9. Gilead Sciences, Inc.
  • 12.10. Celgene Corporation

LIST NOT EXHAUSTIVE

13. Global Red Biotechnology Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us